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Abstract The nuclear factor KB (NF-KB) is thought to be 
crucially involved in the gene activation of several cytokines, 
including tumor necrosis factor a. (TNF). Previously, we showed 
that fibroblast conditioned medium (FCM) is able to inhibit both 
TNF mRNA accumulation and protein release in peripheral 
blood-derived human monocytes (PBM) stimulated with lipopol-
ysaccharide (LPS). In this study we have investigated the effect 
ofFCM on the LPS-induced DNA-binding activity ofNF-KB, by 
means of electrophoretic shift assay (EMSA). We provide 
evidence that FCM strongly inhibits the LPS-induced NFKB 
activation in PBM. Furthermore, we show that exogenous PGE2 
mimics the NFKB inhibitory effect of FCM. On the other hand, 
FCM produced in the presence of indomethacin does not inhibit 
NF-KB activation by LPS. Our results lend further support to the 
hypothesis that inflammatory and immune responses of mono-
cytes/macrophages may be modulated at the molecular level by 
signals originating from tissue structural cells such as fibroblasts. 
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1. Introduction 
Nuclear factor KB (NF-KB) is a heterodimeric transcription 
factor composed of p50 and p65 subunits that belong to the 
protein family NF-KB\Rel\Dorsal (reviewed in [1-3]). All pro-
teins of this family, which currently include the proto-onco-
gene Rei, NF-KB1 (p105 or p50), NF-KB2 (pIOO or p52), Rei 
A (or p65), Rel B in mammalian cells and the Drosophila 
morphogen Dorsal (nomenclature in [4]), share an extensive 
sequence homology at their approx. 300-amino-acid N-ter-
minal region containing both the dimerization and DNA-
binding domains as well as the nuclear localization signal 
(NLS). NF-KB was originally identified as an inducible B 
cell-specific factor able to bind to the decameric KB motif in 
the intronic K light chain enhancer [5]. NF-KB is now recog-
nized to be quite ubiquitously present in most cell types in a 
cytoplasmic, inactive form. In fact, an inhibitor protein, 
IKB(s), typically sequesters the NF-KB complex in the cyto-
plasm by masking NLS and DNA-binding domains. IKB(s) 
also belong to a family of related proteins which include 
IKBa., IKB~, IKBy, Bcl-3 and Drosophila Cactus [6]. A large 
array of stimuli, including viruses, bacterial lipopolysaccha-
ride (LPS), antigen-receptor engagement, stress factors and 
cytokines, may induce a rapid IKB dissociation/degradation 
and subsequently NFKB translocation to the nucleus where 
*Corresponding author. Fax: (39) (95) 310-680/320267. 
it binds decameric KB motifs of the consensus sequence 5'-
GGGRNNYYCC-3' (R = purines, N = any nucleotide, Y = 
pyrimidines) (references in [7]). There is a large set of genes 
with putative KB motifs in their cis-acting elements and in 
many of these the NF-KB binding appears crucial to gene 
regulation. These genes encode defense and signaling proteins 
including cell surface molecules involved in immune function 
such as immunoglobulin K light chain, class I and II major 
histocompatibility complex (MHC) and cytokines such as In-
terleukin-1~ (IL-1 ~), IL-2, IL-6, IL-8, Interferon ~ (INF ~), 
G-CSF, GM-CSF and TNF (reviewed in [8]). In the monocyte 
cell system, NFKB nuclear activity has been shown to be con-
stitutive and thus responsible for the low, but detectable, level 
of TNF transcription [9]. The monocyte cell system (pro-
monocytes, monocytes and tissue macrophages) represents a 
crucial element not only in immune defense, in that these cells 
exert phagocyte function, present processed antigen to T cells 
and orchestrate the immune response by cytokine secretion 
(extensive list of references in [10]), but also in the regulation 
of tissue turnover and repair, inflammation, atherosclerosis 
and tumor growth [11-13]. Previously we showed [14] that 
fibroblasts, the most ubiquitous tissue cells, are able to mod-
ulate LPS-induced TNF production in peripheral blood 
monocytes (PBM). In this study, we have investigated the 
effect of soluble factor(s) released by actively proliferating 
lung fibroblast on NFKB activation in adherent human 
PBM stimulated with LPS. We provide evidence that FCM 
strongly inhibits the LPS-induced nuclear mobilization of 
NFKB. Furthermore, we have investigated the effect of exo-
genous PGE2 on NF-KB activation, as we had detected sig-
nificant amounts of spontaneously released PGE2 in FCM 
and observed that FCM lost its inhibitory capability when it 
was produced in the presence of the cyclooxygenase inhibitor 
indomethacin. We show that exogenous PGE2 inhibits, in a 
dose-dependent manner, the NFKB nuclear mobilization in-
duced by LPS in human adherent PBM. 
2. Materials and methods 
2.1. Fibroblast conditioned medium 
Fibroblast conditioned medium was generated from cultures of 
2 X 106 fibroblasts incubated for 24 h in 10 ml of supplemented 
RPM I (Gibco, Paisley, UK): 10% fetal calf serum (Gibco), penicil-
lin/streptomicin, L-glutamine (2 mM). In some cases fibroblasts were 
cultured in the presence of indomethacin (5 X 10-5 M, Sigrna, St. 
Louis, MO). All supernatants were then centrifuged and stored in 
aliquots at -20°C until use. 
2.2. Fibroblast cultures 
Primary lines of normal human adult lung fibroblasts were estab-
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Ii shed using an outgrowth from explants from histologically normal 
areas of surgical lung specimens from patients undergoing resective 
surgery for cancer according to the method of Jordana and co-work-
ers [IS]. Aliquots of the cells were frozen and stored in liquid nitrogen. 
In all experiments we used cell lines at a passage earlier than the 
eighth. 
2.3. Monocyte isolation procedure 
Peripheral blood monocytes (PBM) were obtained from healthy 
donors as described by Colotta and associates [16] under LPS-free 
conditions. Monocyte purity was > 90% as assessed by morphology 
and non-specific esterase staining. 
2.4. Adherent monocyte cultures 
PBM were plated at a concentration of 5 x 105 cells/ml of supple-
mented (as described above) RPM I in 10 cm dishes and allowed to 
adhere in a humidified atmosphere of 5% CO2 at 37°C. After 2 h, the 
medium was removed and fresh supplemented RPMI or FCM was 
added. Cells were then immediately stimulated with lipopolysaccha-
ride (LPS from E. coli, Sigma, 10 I-lg/ml) and incubated for 2 h. 
2.5. Prostaglandin E2 assay 
Concentrations of PGE2 in FCM were determined using a commer-
cially available enzyme immunoassay, according to the manufacturer's 
instructions (PGE2 enzyme immunoassay kit, Cayman Chemical Co., 
Ann Arbor, MI, USA). The assay is sensitive to 3.9 pg/ml of PGE2 . 
All samples were determined in triplicate. 
2.6. Nuclear extract preparation 
The nuclear protein extracts were prepared according to the proto-
col of Dignam et al. [17] with some modifications. Briefly, after the 
established times of culture, the cells were washed twice with PBS and 
then harvested with a rubber policeman in I ml cold buffer contain-
ing: 10 mM HEPES, pH 7.9,10 mM KCI, 0.2 mM EDTA, 0.2 mM 
EGTA, I mM dithiothreitol (DTT), 0.5 mM phenylmethanesulphonyl 
fluoride (PMSF), 10 ~g/ml aprotinin, 10 ~g/mlleupeptin and 10 ~g/ml 
pepstatin. After IS min on ice, Nonidet P40, 0.1% (v/v), was added to 
the homogenates and the tubes were vigorously rocked. Then the 
homogenates were centrifuged (I X 104 Xg) for 50 s in a microcentri-
fuge at 4°C. The nuclear pellets were resuspended in 30 ml of ice-cold 
buffer (20 mM HEPES, pH 7.9, 0.4 M NaC!, 0.2 mM EDTA, 0.2 mM 
EGTA, I mM DTT, 0.5 mM PMSF, 10 ).tg/ml aprotinin, 10 ).tg/ml 
leupeptin and 10 ~g/ml pepstatin) and vigorously rocked at 4°C for 15 
min. The nuclear extracts were centrifuged for 10 min at 4°C and the 
supernatants were stored in aliquots at -80°C. The protein content 
was estimated with a kit for protein microdetermination (Biorad). 
2.7. Electrophoretic mobility shift assay (EMSA) and gel supershift 
Nuclear extracts (5 ~g of protein) were incubated with 30000 cpm 
of a commercially obtained double-stranded oligonucleotide (Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA, USA), of 20 bp containing 
the (underlined) NF-KB consensus sequence (5'-AGT TGA GGG 
GAC TTT CCC AGG C-3') labeled with [y_32P]ATP (10 mCi/ 
mmol) by T4 polynucleotide kinase (Boehringer, Mannheim, Ger-
many) and purified on a spin Sephadex G-25 column (Pharmacia, 
Uppsala, Sweden). Incubations were performed for 30 min in the 
presence of 50 ~g/ml of poly(dI-dC), 1 mg/ml nuclease-free BSA 
and binding buffer containing 100 mM Tris base, 400 mM KCI, 5 
mM DTT, 0.5% NP-40, 25% glycerol. Samples were then electro-
phoresed through a 4% polyacrylamide gel for 2 h at 200 V. Gels 
were exposed to X-ray film with intensifying screens for 6-18 h. In 
some EMSAs unlabeled oligonucleotide was added in molar excess 
(IOOx) as specific binding competitor for 30 min at room temperature 
before incubating samples. For gel supershift nuclear extract were pre-
incubated (20 min at room temperature) with anti p-50 or anti p65 
antibodies (SantaCruz Biotechnology). 
3. Results 
3.1. Effect of fibroblast conditioned medium (FCM) on 
LPS-induced NF1\.B activation 
Preliminary experiments, with very similar results, were per-
formed by pre-incubating monocytes in FCM for 60, 30, 15 or 
o min before LPS treatment. Thus, in all experiments LPS was 
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Fig. I. Fibroblast conditioned medium (FCM) inhibits LPS-induced 
NF-KB activation in adherent human PBM. Electrophoretic mobility 
shift assay (EMSA) result (1 of 10 experiments) obtained using a 
32P-Iabeled oligonucleotide containing an NF-KB binding sequence 
and nuclear extracts from unstimulated monocytes (lane I), mono-
cytes stimulated with LPS (I 0 ~g/ml) in the absence (lane 2) or 
presence of FCM (lane 3). As a specificity control, nuclear extracts 
as in lane 2 were pre-incubated with a 100 X molar excess of cold 
probe (lane 4). Immunologically characterized NF-KB complexes are 
denoted I (p50-p65) and II (pSO-p50). 
added simultaneously with FCM. As shown in Fig. 1, the 
specific DNA binding of NF1\.B complexes induced in adher-
ent human PBM stimulated wit)J. LPS was strongly inhibited 
in the presence of FCM. The specificity of NF1\.B binding was 
shown by the complete disappearance of labeled complexes, 
which was indicated as I and II, in the competition assay with 
a molar excess of unlabeled probe and by a supershift of 
complexes in the presence of anti p-50 and/or anti p65 anti-
bodies (data not shown). According to Ziegler-Heitbrock et 
al. [18], we assume that complex I represents the p50-p65 
heterodimer (NF1\.B) and complex II represents the p50-p50 
homodimer. It is noteworthy that in 3 out of 10 experiments 
the NF-1\.B complexes were fully activated in resting mono-
cytes and no further activation was induced by LPS. In these 
experiments FCM reduced the baseline level of NF1\.B DNA-
binding activity (data not shown). 
3.2. PGE2 amounts in FCM 
In order to identify the soluble factor(s) responsible for 
blocking LPS-induced NF1\.B activation we measured the 
PGE2 content in FCM. In fact, fibroblasts spontaneously re-
leased PGE2 into the medium (1.208 ± 0.140 ng/ml, equivalent 
to about 3.4 X 10-9 M). We also produced FCM in the pres-
ence of indomethacin and determined PGE2• As expected, 
the addition of indomethacin to fibroblast cultures caused a 
100-fold reduction of PGE2 content (19 ± 7 pg/ml equivalent 
to 5.67x 10-12 M). 
3.3. Effect of PGE2-depleted FCM on LPS-induced NF1\.B 
activation 
As Fig. 2 shows, the FCM generated in the presence of 
indomethacin hardly reduced the NF1\.B activity. 
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Fig. 2. PGE2-depleted FCM does not inhibit LPS-induced NF-KB 
nuclear mobilization. EMSA result (I of 3 experiments) obtained 
using a 32P-labeled oligonucleotide containing an NF-KB binding se-
quence and nuclear extracts from unstimulated monocytes (lane I), 
monocytes stimulated with LPS, 10 ~glml (lane 2), monocytes stim-
ulated with LPS in the presence of FCM generated with indo-
methacin (lane 3) and monocytes stimulated with LPS in the pres-
ence of normal FCM (lane 4). Activated NF-KB complexes are 
indicated. 
3.4. Effect of exogenous PGE2 on LPS-induced NFKB 
activation 
In our experiments, the addition of exogenous PGE2, at the 
same time as LPS stimulation, mimicked the FCM inhibitory 
effect on NFKB activation by LPS. Fig. 3 demonstrates that 
the inhibitory effect started from a concentration threshold of 
PGE2 (10-9 M) which is comparable to the PGE2 concentra-
tion in FCM. 
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Fig. 3. Dose-dependent effect of exogenous PGE2 on LPS-induced 
NF-KB nuclear mobilization. EMSA result (I of 3 experiments) ob-
tained using a 32P-labeled oligonucleotide containing an NF-KB 
binding sequence and nuclear extracts from unstimulated monocytes 
(lane I), monocytes stimulated with LPS, 10 ~glml (lane 2) and 
monocytes stimulated with LPS in the presence of increasing con-
centrations of exogenous PGE2 (0.1, I, 10 nglml: lanes 3, 4, 5, re-
spectively). The arrow indicates the unresolved NFkB complexes. 
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Fig. 4. FCM does not influence the activity of the cyclic AMP re-
sponse element binding (CREB) transcription factor. EMSA result 
using a 32P-labeled oligonucleotide containing a CREB binding se-
quence and nuclear extracts from unstimulated monocytes (lane I), 
monocytes stimulated with LPS, 10 ~glml (lane 2) and monocytes 
stimulated with LPS in the presence of FCM (lane 3). Two adjacent 
CREB complexes [19] are indicated. 
3.5. Effect of FCM on the activity of the unrelated 
transcription factor CREB 
To verify the specificity of the FCM inhibition of LPS-in-
duced NFKB activity we also investigated the possible effect 
on the activity of the cyclic AMP response element binding 
(CREB) transcription factor. As reported by others [19], nu-
clear extracts from monocytes (stimulated or not with LPS) 
showed a strong binding activity with labeled CRE oligonu-
cleotides in EMSA. As shown by Fig. 4, FCM treatment did 
not affect CREB binding activity in monocytes. 
4. Discussion 
Mononuclear phagocytes are important regulators of im-
mune, inflammatory and fibrotic response. These functions 
are mediated through the production of several cytokines, 
including TNF, IL-I, IL-6, IL-8 and GM-CSF. In response 
to pathological stimuli, blood monocytes extravasate to the 
tissue and orchestrate the immune/inflammatory response by 
secretion of such cytokines. This process is normally tuned by 
a fine balance of stimulatory and inhibitory signals. A failure 
of this balanced tuning may lead to pathological conditions 
such as septic shock or chronic inflammation. We previously 
reported that tissue structural cells such as fibroblasts may 
modulate immune/inflammatory responses [14,20--23]. In this 
report, we show that a soluble factor(s) spontaneously re-
leased by actively proliferating lung fibroblasts is able to in-
hibit specifically the nuclear mobilization of the pivotal tran-
scription factor NFKB in human adherent PBM stimulated 
with LPS. Mechanisms by which LPS activates mononuclear 
phagocytes, its major cellular target, have not yet been com-
pletely characterized. LPS provokes multiple effects on mono-
nuclear phagocytes including NF-KB mobilization [24], cyto-
kine gene activation and release [25-27]. Several cell surface 
molecules such as CDI4, CDlllCDl8 are able to recognize 
the lipid A portion of the polysaccharide region of the LPS 
molecule [28,29]. The interaction of LPS with cell membrane 
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receptors may trigger different signal transduction pathways. 
There is much evidence that LPS activates protein kinase C 
(PKC) [30], protein tyrosine kinases (PTK [31,32]), mitogen-
activated protein (MAP) kinases [33] and a pair of closely 
related MAP kinase homologues, termed CSBPs (cytokine-
suppressive anti-inflammatory drug binding proteins), recently 
cloned and biochemically characterized [34]. In any case, pro-
tein phosphorylation seems to be the key event in the mono-
nuclear phagocyte response to LPS [35], inducing NF-KB nu-
clear mobilization. In fact, phosphorylation has been shown 
to be a fundamental step in the activation of NF-KB [36]. 
Even though we can only speculate on which LPS-triggered 
pathway(s) leading to NFKB activation could be affected by 
FCM, the inhibitory effect of FCM soluble factor(s) could 
rely on the impairment of kinase activation triggered by 
LPS. Nevertheless, in order to identify the inhibitory factor(s) 
we measured PGE2 content (10-9 M) in the FCM, as it has 
been shown that PGE2 is able to abolish the NFKB binding 
activity in stimulated human Th cell clones [37] as well as in 
mesangial cells [38]. Moreover, it has been shown that PGE2 
can act as a negative regulator of various lymphocyte and 
macrophage activities including cytotoxicity for tumor target 
cells [39], response to migration inhibitors [40], phorbol myr-
istate acetate (PMA)-triggered production of ROIs [41] and 
cytokine production [42,43]. In this report, we show that exo-
genous PGE2 (10-9_10-8 M) is able to suppress LPS-induced 
NFKB activation in human adherent PBM. We also show that 
FCM produced in the presence of indomethacin, a cyclooxy-
genase inhibitor which efficaciously depleted PGE2 , failed to 
inhibit, at least in part, NFKB activation. These data indicate 
a major role of PGE2 in the inhibition exerted by FCM on 
LPS-induced NFKB activation, even though we cannot rule 
out the contribution of other soluble factor(s). Based on our 
in vitro findings, we hypothesize that the exchange of cross-
talks between monocytes/macrophages and fibroblasts, which 
relies on soluble factors such as cytokines and PGE2, could be 
an important in vivo mechanism leading to the modulation of 
inflammatorylimmune response, as well as fibrotic response, 
via the control of the pivotal transcription factor NFKB. 
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